None listed
Conditions
Brief summary
The purpose of this study is to determine if specific immune system cells, called dendritic cells, have a role in patients with non-small-cell lung carcinoma undergoing anti-PD-1 immunotherapy. Who is it for? You may be eligible for this study is you are an adult who has confirmed non-small-cell lung carcinoma. Study details Patients from Monash Medical Centre with non-small-cell lung carcinoma to be treated with anti-PD-1 immunotherapy who consent to this study, will have blood samples taken at baseline (before commencing therapy) and prior to each treatment cycle (approximately every 2 to 3 weeks). The blood and serum samples will then be used to test for inflammatory markers. Additionally, participants archival tissue samples will also be used to detect dendritic cells and expression of PD-1. The identification of markers associated treatment response would allow for greater accuracy in selecting potential responders to treatment.
Interventions
Patients with non-small-cell lung carcinoma who will be receiving anti-PD-1 immunotherapy as 1st or 2nd line therapy as standard of care will have serial blood samples taken at baseline and prior to each cycle for as long as they remain on therapy for up to 2 years or until death. Serum will be analysed for a panel of inflammatory cytokines. Participants will also be asked for access to archival tumour tissue samples for analysis using immunohistochemistry staining for dendritic cell sub-populat
Patients with non-small-cell lung carcinoma who will be receiving anti-PD-1 immunotherapy as 1st or 2nd line therapy as standard of care will have serial blood samples taken at baseline and prior to each cycle for as long as they remain on therapy for up to 2 years or until death. Serum will be analysed for a panel of inflammatory cytokines. Participants will also be asked for access to archival tumour tissue samples for analysis using immunohistochemistry staining for dendritic cell sub-populations.
Sponsors
Monash Health Oncology Department
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Histologically confirmed NSCLC Commencing anti-PD-1 immunotherapy as 1st or 2nd line therapy. Eastern Cooperative Oncology Group (ECOG) perfomance score 0-2 Informed consent given for participation
Exclusion criteria
Life expectancy less than 12 weeks
Outcome results
None listed